HEART AND VESSELS is a prominent peer-reviewed journal published by SPRINGER, dedicated to advancing the fields of cardiology and cardiovascular medicine. With its ISSN 0910-8327 and E-ISSN 1615-2573, this esteemed journal encompasses a broad range of topics pertinent to heart health, vascular function, and associated therapies, making it an essential resource for researchers, clinicians, and healthcare professionals alike. Based in Japan and operating since 1985, HEART AND VESSELS has consistently maintained a Q2 ranking in the 2023 category quartiles, highlighting its relevance and impact in the cardio domain. Although it does not offer open access, the journal ensures high-quality publications that contribute significantly to the academic and clinical understanding of cardiovascular health. With over three decades of continuous scholarly contribution, HEART AND VESSELS serves as a vital platform for disseminating cutting-edge research and fostering innovative practices in the management of cardiovascular diseases.

Current Opinion in Lipidology is a premier journal published by Lippincott Williams & Wilkins, offering critical insights into the ever-evolving landscape of lipid research. With an impressive convergence spanning from 1990 to 2024, this journal serves as an essential platform for researchers, clinicians, and professionals dedicated to the study of lipids in relation to cardiovascular health, endocrinology, and metabolism. The journal currently holds a distinguished Q1 ranking in Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Nutrition and Dietetics, showcasing its significant impact in these fields. Additionally, it ranks in the Q2 quartile for Cell Biology and Molecular Biology, underlining its comprehensive approach to lipidology. Though not open access, the content is rich with cutting-edge reviews, clinical studies, and expert opinions that aim to advance knowledge and practice in lipid metabolism, making it a valuable resource for anyone seeking to stay abreast of the latest developments in lipid research.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, the esteemed publication of Elsevier Science Inc, stands as a premier platform for advancing knowledge in the field of cardiology and cardiovascular medicine. With an impressive impact factor reflecting its prominence—ranked Q1 in its category for 2023 and occupying the 4th position out of 387 in the Scopus listings, firmly placing it in the 99th percentile—this journal is essential for researchers, clinicians, and students alike. Since its inception in 1983, it has continuously provided a vital space for high-quality research and innovative clinical practices, driving forward our understanding of cardiovascular health. While access options are not open, the value of the cutting-edge articles published here cannot be overstated, as they foster collaboration and inform better patient care across the globe. As part of its ongoing commitment to excellence, the journal solicits submissions of original research, reviews, and clinical studies that contribute meaningfully to the field and engage its diverse readership.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

Acta Angiologica, published by VIA MEDICA, is an Open Access journal dedicated to the dynamic field of cardiology and cardiovascular medicine. Since its inception in 1995, this esteemed journal has provided a vital platform for the dissemination of cutting-edge research and innovative medical practices, especially pertinent to vascular health. Being indexed in Scopus, it holds a rank of #352 out of 387 in its category for 2023, positioning it in the 9th percentile among contemporaneous journals. The journal's commitment to scholarly excellence and accessibility is underscored by its embrace of open access publishing, allowing researchers, professionals, and students to engage with vital advancements in the field without financial barriers. With a converged timeline from 2005 to 2024, Acta Angiologica continues to play a crucial role in bridging gaps in cardiovascular knowledge, fostering collaboration across disciplines, and advancing the implementation of preventative and therapeutic strategies in vascular medicine. Located in Gdansk, Poland, the journal is poised to make significant contributions to the cardiovascular research landscape.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.